4.7 Article

γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C A cross-sectional study

期刊

NEUROLOGY
卷 76, 期 4, 页码 366-372

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318208f4ab

关键词

-

资金

  1. Swedish Research Council [14002, 2006-6227, 2006-2740, 2006-3505]
  2. Alzheimer's Association [NIRG-08-90356]
  3. cNEUPRO
  4. Royal Swedish Academy of Sciences
  5. Sahlgrenska University Hospital
  6. Soderberg Foundation
  7. Gothenburg Medical Society
  8. Swedish Medical Society
  9. Swedish Brain Power
  10. Stiftelsen Gamla Tjanarinnor
  11. Lundbeck Foundation
  12. Gun och Bertil Stohnes stiftelse
  13. Ahlen-stiftelsen
  14. Swedish Brain Fund
  15. Alzheimer Foundation, Sweden
  16. Dementia Association, Sweden
  17. NIH Office of Rare Diseases
  18. Eunice Kennedy Shriver National Institute of Child Health and Human Development
  19. Gamla Tjanarinnor
  20. Pfannenstills stiftelse
  21. Demensfonden
  22. Thureus stiftelse
  23. Anna-Lisa och Bror Bjornssons stiftelse
  24. Hjarnfonden
  25. Svenska Lakaresallskapet
  26. Neurologiskt handikappades riksforbund
  27. Goteborgs lakaresallskap
  28. Swedish Research Council
  29. Alzheimer's Association
  30. NIH/NICHD
  31. Ara Parseghian Medical Research Foundation
  32. Dana's Angels Research Trust
  33. NIH
  34. Ara Paseghian Medical Research Foundation
  35. Innogenetics
  36. Bristol-Myers Squibb
  37. Swedish Brain Power project
  38. Swedish Council for Working Life and Social Research
  39. Swedish Alzheimer Foundation
  40. Stiftelsen for Gamla Tjanarinnor
  41. King Gustaf V's and Queen Victoria's Foundation

向作者/读者索取更多资源

Objective: Niemann-Pick disease type C (NPC) is an inherited disorder characterized by intracellular accumulation of lipids such as cholesterol and glycosphingolipids in endosomes and lysosomes. This accumulation induces progressive degeneration of the nervous system. NPC shows some intriguing similarities with Alzheimer disease (AD), including neurofibrillary tangles, but patients with NPC generally lack amyloid-beta (A beta) plaques. Lipids affect gamma-secretase-dependent amyloid precursor protein (APP) metabolism that generates A beta in vitro, but this has been difficult to prove in vivo. Our aim was to assess the effect of altered lipid constituents in neuronal membranes on amyloidogenic APP processing in humans. Methods: We examined A beta in CSF from patients with NPC (n = 38) and controls (n = 14). CSF was analyzed for A beta(38), A beta(40), A beta(42), alpha-cleaved soluble APP, beta-cleaved soluble APP, total-tau, and phospho-tau. Results: A beta release was markedly increased in NPC, with a shift toward the A beta(42) isoform. Levels of alpha(-) and beta-cleaved soluble APP were similar in patients and controls. Patients with NPC had increased total-tau. Patients on treatment with miglustat (n = 18), a glucosylceramide synthase blocker, had lower A beta(42) and total-tau than untreated patients. Conclusion: Increased CSF levels of A beta(38), A beta(40), and A beta(42) and unaltered levels of beta-cleaved soluble APP are consistent with increased gamma-secretase-dependent A beta release in the brains of patients with NPC. These results provide the first in vivo evidence that neuronal lipid accumulation facilitates gamma-secretase-dependent A beta production in humans and may be of relevance to AD pathogenesis. Neurology (R) 2011;76:366-372

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据